Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oxygen carrier YQ23

A bovine-derived, stabilized, non-polymeric, cross-linked, tetrameric hemoglobin-based oxygen carrier, with potential oxygen carrying, immunomodulating and antineoplastic activities. Upon administration, oxygen carrier YQ23 may increase the oxygen level in the tumor microenvironment (TME). This may prevent the increase of circulating endothelial progenitor cells (EPCs) and regulatory T cells (Tregs) that results from tissue ischemia and hypoxia. EPCs play important roles in tumor vasculogenesis, tumor growth and metastases. Tregs play an important role in antitumor immune responses.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	hemoglobin-based oxygen carrier solution YQ23
Code name:	YQ 23 YQ-23 YQ23

oxygen carrier YQ23

Search NCI's Drug Dictionary